Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul;98(30):e16632.
doi: 10.1097/MD.0000000000016632.

Efficacy of mometasone furoate for nasal polyps: A protocol for systematic review of randomized controlled trial

Hai-Jiang Yu  1 , Lin Han  2 , Wei-Feng Wang  3 , Lin-Hong Yang  1 , Yu-Fei Nie  4
Affiliations

Efficacy of mometasone furoate for nasal polyps: A protocol for systematic review of randomized controlled trial

Hai-Jiang Yu et al. Medicine (Baltimore). 2019 Jul.

Abstract

Background: This study aims to systematically explore the efficacy and safety of mometasone furoate (MTF) for patients with nasal polyps (NP).

Methods: We will search MEDLINE, Cochrane Library, PubMed, Springer, Web of Science, Ovid, Wangfang and Chinese Biomedical Literature Database from their inception to April 30, 2019 without language restrictions. All randomized controlled trials (RCTs) of MTF for the treatment of NP will be considered for inclusion. RevMan 5.3 software will be used for data synthesis, subgroup analysis, sensitivity analysis, as well as the meta-analysis.

Results: Primary outcomes include change in symptom scores (as measured by any symptom scores), and polyp size (as assessed by any Polyp size scores or tools). Secondary outcomes consist of polyp recurrence, change in nasal air flow, quality of life outcomes (as measured by any quality of life scales, such as Short Form Health Survey is a 36-item), and adverse events.

Conclusion: This study will provide evidence for judging whether MTF is an effective and safe treatment for NP or not.

Prospero registration number: PROSPERO CRD42019134037.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest.

References

    1. Yousefi J, Madarshahi H, Akhavan A, et al. Effect of ESS on olfactory threshold of patients with CRS without Nasal Polyps. Int Tinnitus J 2018;22:89–92. - PubMed
    1. Avdeeva K, Fokkens W. Precision medicine in chronic rhinosinusitis with nasal polyps. Curr Allergy Asthma Rep 2018;18:25. - PMC - PubMed
    1. Marioni G, Zanotti C, Brescia G. Chronic rhinosinusitis with nasal polyps in the elderly: assessing current evidence. Allergy Asthma Proc 2018;39:9–13. - PubMed
    1. Langdon C, Mullol J. Nasal polyps in patients with asthma: prevalence, impact, and management challenges. J Asthma Allergy 2016;9:45–53. - PMC - PubMed
    1. Dietz de Loos DA, Hopkins C, Fokkens WJ. Symptoms in chronic rhinosinusitis with and without nasal polyps. Laryngoscope 2013;123:57–63. - PubMed

Substances